In-Depth Analysis of the Impact of Different Serum-Free Media on the Production of Clinical Grade Dendritic Cells for Cancer Immunotherapy
Open Access
- 5 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Abstract
Dendritic cell (DC)-based antitumor vaccines have proven to be a safe approach, but often fail to generate robust results between trials. Translation to the clinic has been hindered in part by the lack of standard operation procedures for vaccines production, namely the definition of optimal culture conditions during ex-vivo DC differentiation. Here we sought to compare the ability of three clinical grade serum-free media, DendriMACS, AIM-V, and X-VIVO 15, alongside with fetal bovine serum-supplemented Roswell Park Memorial Institute Medium (RPMI), to support the differentiation of monocyte-derived DCs (Mo-DCs). Under these different culture conditions, phenotype, cell metabolomic profiles, response to maturation stimuli, cytokines production, allogenic T cell stimulatory capacity, as well as priming of antigen-specific CD8+ T cells and activation of autologous natural killer (NK) cells were analyzed. Immature Mo-DCs differentiated in AIM-V or X-VIVO 15 presented lower levels of CD1c, CD1a, and higher expression of CD11c, when compared to cells obtained with DendriMACS. Upon stimulation, only AIM-V or X-VIVO 15 DCs acquired a full mature phenotype, which supports their enhanced capacity to polarize T helper cell type 1 subset, to prime antigen-specific CD8+ T cells and to activate NK cells. CD8+ T cells and NK cells resulting from co-culture with AIM-V or X-VIVO 15 DCs also showed superior cytolytic activity. 1H nuclear magnetic resonance-based metabolomic analysis revealed that superior DC immunostimulatory capacities correlate with an enhanced catabolism of amino acids and glucose. Overall, our data highlight the impact of critically defining the culture medium used in the production of DCs for clinical application in cancer immunotherapy. Moreover, the manipulation of metabolic state during differentiation could be envisaged as a strategy to enhance desired cell characteristics.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (UIDB/04501/2020, UIDB/50011/2020, UIDP/50011/2020, PD/BDE/135076/2017, PD/BD/147220/2019)
- European Regional Development Fund (POCI-01-0247-FEDER-033532)
- Universidade de Coimbra
This publication has 58 references indexed in Scilit:
- Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28Blood, 2011
- Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant GliomaJournal of Clinical Oncology, 2011
- Lipid Signaling in T-Cell Development and FunctionCold Spring Harbor Perspectives in Biology, 2010
- Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activationBlood, 2010
- CD1a expression defines an interleukin-12 producing population of human dendritic cellsClinical and Experimental Immunology, 2008
- Differentiation of CD1a− and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARγBlood, 2006
- Th1-Polarizing Capacity of Clinical-Grade Dendritic Cells Is Triggered by Ribomunyl but Is Compromised by PGE2Journal of Immunotherapy, 2005
- A role for Mer tyrosine kinase in αvβ5 integrin-mediated phagocytosis of apoptotic cellsJournal of Cell Science, 2005
- Identification of a factor that links apoptotic cells to phagocytesNature, 2002
- A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injectionInternational Journal of Cancer, 2001